NI201000001A - Nuevos cristales y procesos para elaborar 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico. - Google Patents

Nuevos cristales y procesos para elaborar 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico.

Info

Publication number
NI201000001A
NI201000001A NI201000001A NI201000001A NI201000001A NI 201000001 A NI201000001 A NI 201000001A NI 201000001 A NI201000001 A NI 201000001A NI 201000001 A NI201000001 A NI 201000001A NI 201000001 A NI201000001 A NI 201000001A
Authority
NI
Nicaragua
Prior art keywords
phenyl
amino
propionyl
dimethyl
ethyl
Prior art date
Application number
NI201000001A
Other languages
English (en)
Inventor
Anzalone Luigi
J Villani Frank
Allan Teleha Christopher
Feibush Penina
Fegely Barry
Original Assignee
Furiex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Furiex Pharmaceuticals Inc filed Critical Furiex Pharmaceuticals Inc
Publication of NI201000001A publication Critical patent/NI201000001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos cristales de 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico y los métodos para elaborar el zwitterion de 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzóico.
NI201000001A 2007-07-09 2010-01-07 Nuevos cristales y procesos para elaborar 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico. NI201000001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94858407P 2007-07-09 2007-07-09

Publications (1)

Publication Number Publication Date
NI201000001A true NI201000001A (es) 2010-07-22

Family

ID=39926468

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000001A NI201000001A (es) 2007-07-09 2010-01-07 Nuevos cristales y procesos para elaborar 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico.

Country Status (25)

Country Link
US (7) US7994206B2 (es)
EP (1) EP2176234B1 (es)
JP (5) JP5702140B2 (es)
KR (2) KR101690161B1 (es)
CN (3) CN101730685A (es)
AU (1) AU2008275270C1 (es)
BR (1) BRPI0813632A2 (es)
CA (1) CA2695126C (es)
CO (1) CO6260079A2 (es)
CR (1) CR11260A (es)
EA (1) EA020024B1 (es)
EC (1) ECSP109863A (es)
ES (1) ES2567077T3 (es)
HK (1) HK1141519A1 (es)
HU (2) HUE028538T2 (es)
IL (1) IL203081A (es)
MX (1) MX339569B (es)
MY (1) MY174681A (es)
NI (1) NI201000001A (es)
NZ (1) NZ582420A (es)
PH (1) PH12016502561A1 (es)
SG (1) SG185941A1 (es)
UA (1) UA104713C2 (es)
WO (1) WO2009009480A2 (es)
ZA (1) ZA201000921B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7412462B2 (en) 2000-02-18 2008-08-12 Burnside Acquisition, Llc Data repository and method for promoting network storage of data
NZ582420A (en) 2007-07-09 2011-11-25 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({ [2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino} -methyl)-2-methoxy- benzoic acid
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP3325450A1 (en) * 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
WO2018055528A2 (en) * 2016-09-20 2018-03-29 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018069770A1 (en) * 2016-10-14 2018-04-19 Allergan Holdings Unlimited Company Methods of treatment using eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
EP3573958A1 (en) 2017-01-27 2019-12-04 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018198101A2 (en) * 2017-04-25 2018-11-01 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline form of eluxadoline
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
CA3018321A1 (en) * 2017-09-25 2019-03-25 Apotex Inc. Novel crystalline form of eluxadoline
US10298921B1 (en) * 2018-02-27 2019-05-21 Looking Glass Factory, Inc. Superstereoscopic display with enhanced off-angle separation
WO2020039333A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2021198780A1 (en) * 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003065441A (ja) 2001-08-28 2003-03-05 Japan Matekkusu Kk パッキン材料及びこの材料を用いたグランドパッキン
SI2653465T1 (sl) * 2004-03-15 2016-10-28 Janssen Pharmaceutica N.V. Modulatorji opiodnih receptorjev
EA015512B1 (ru) * 2005-03-14 2011-08-30 Янссен Фармацевтика, Н.В. Способ получения опиоидных модуляторов
NZ582420A (en) 2007-07-09 2011-11-25 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({ [2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino} -methyl)-2-methoxy- benzoic acid

Also Published As

Publication number Publication date
IL203081A (en) 2016-09-29
JP2016128433A (ja) 2016-07-14
JP5702140B2 (ja) 2015-04-15
CR11260A (es) 2013-01-25
KR20150080006A (ko) 2015-07-08
US20110263868A1 (en) 2011-10-27
AU2008275270A1 (en) 2009-01-15
CN105111149A (zh) 2015-12-02
EA201070116A1 (ru) 2010-06-30
JP2010533191A (ja) 2010-10-21
PH12016502561A1 (en) 2017-09-04
ZA201000921B (en) 2011-04-28
WO2009009480A3 (en) 2009-03-12
US9115091B2 (en) 2015-08-25
JP6321690B2 (ja) 2018-05-09
SG185941A1 (en) 2012-12-28
KR101690161B1 (ko) 2016-12-27
US8859604B2 (en) 2014-10-14
EP2176234A2 (en) 2010-04-21
CN111620823A (zh) 2020-09-04
ES2567077T3 (es) 2016-04-19
WO2009009480A2 (en) 2009-01-15
HUS1700011I1 (hu) 2017-04-28
NZ582420A (en) 2011-11-25
BRPI0813632A2 (pt) 2014-12-23
US20140011851A1 (en) 2014-01-09
US20090018179A1 (en) 2009-01-15
CA2695126A1 (en) 2009-01-15
KR20100043210A (ko) 2010-04-28
JP2015129154A (ja) 2015-07-16
CO6260079A2 (es) 2011-03-22
JP5852625B2 (ja) 2016-02-03
CN101730685A (zh) 2010-06-09
US9364489B2 (en) 2016-06-14
EA020024B1 (ru) 2014-08-29
JP2018123144A (ja) 2018-08-09
US20150099724A1 (en) 2015-04-09
MY174681A (en) 2020-05-07
EP2176234B1 (en) 2016-01-27
HK1141519A1 (zh) 2010-11-12
ECSP109863A (es) 2010-02-26
CA2695126C (en) 2018-10-30
JP2014144946A (ja) 2014-08-14
KR101590596B1 (ko) 2016-02-01
JP5870220B2 (ja) 2016-02-24
MX339569B (es) 2016-05-31
US9789125B2 (en) 2017-10-17
US8691860B2 (en) 2014-04-08
AU2008275270C1 (en) 2014-04-17
HUE028538T2 (en) 2016-12-28
US20160015724A1 (en) 2016-01-21
US20140221444A1 (en) 2014-08-07
US7994206B2 (en) 2011-08-09
UA104713C2 (ru) 2014-03-11
US8609865B2 (en) 2013-12-17
US20160354389A1 (en) 2016-12-08
AU2008275270B2 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
NI201000001A (es) Nuevos cristales y procesos para elaborar 5 - ( { [ 2 - amino - 3 - ( 4 - carbamoil - 2, 6 -dimetil - fenil ) - propionil] - [1 - (4 - fenil - 1h - imidazol - 2 - il ) - etil ] - amino } - metil ) - 2 - ácido metoxibenzoico.
CR20110260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o un diurético
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
BRPI0810991A2 (pt) Método para a produção de um composto de amida.
LTC2404919I2 (lt) Heterociklinis junginys, tinkamas panaudoti kaip ATP-rišančių kasečių transporterių moduliatorius
EA201071151A1 (ru) Внутриматочная система
EA201170872A1 (ru) Ингибиторы протеинкиназы
SMT201400032B (it) Acetammidi n-(etero)arile, 2-(etero)arile sostituite per l'impiego come modulatori di segnalazione wnt
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
UA110600C2 (uk) Спосіб отримання захищених похідних l-аланіну
DK2010496T3 (da) 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
BRPI0810660A2 (pt) Derivados do ácido lipóico
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201391744A1 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf
BR112015022753A2 (pt) formulações de dosagens de moduladores de receptor opióide
MX2012015021A (es) 5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p).
EA201190256A1 (ru) Способ снижения уровня убиквитинилированных белков
EA201300719A2 (ru) Способ ферментативного синтеза (7s)-1-(3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил) n-метилметанамина и применение в синтезе ивабрадина и его солей
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CL2011000297A1 (es) Procedimiento de sintesis de ivabradina utilizando un intermediario de hemitioacetal; y los compuestos intermediarios considerados.